Document ID: FDA-2022-N-0001-0001
Agency: fda
Document Type: Notice
Title: Science Advisory Board to the National Center for Toxicological Research Advisory Committee; Notice of Meeting
Posted Date: 2022-04-20T04:00Z

[Federal Register Volume 87, Number 76 (Wednesday, April 20, 2022)]
[Notices]
[Pages 23522-23523]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-08460]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2022-N-0001]

Science Advisory Board to the National Center for Toxicological 
Research Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) announces a 
forthcoming public advisory committee meeting of the Science Advisory 
Board to the National Center for Toxicological Research. The general 
function of the committee is to provide advice and recommendations to 
the Agency on research being conducted at the National Center for 
Toxicological Research (NCTR). At least one portion of the meeting will 
be closed to the public.

DATES: The meeting will be held virtually on May 18, 2022, from 8 a.m. 
to 5:55 p.m., Central Standard Time, and on May 19, 2022, from 8 a.m. 
to 11:30 a.m., Central Standard Time.

ADDRESSES: Please note that due to the impact of this COVID-19 
pandemic, all meeting participants will be joining this advisory 
committee meeting via an online teleconferencing platform. Answers to 
commonly asked questions about FDA advisory committee meetings may be 
accessed at: https://www.fda.gov/advisory-committees/about-advisory-committees/common-questions-and-answers-about-fda-advisory-committee-meetings. The meeting will be webcast both days and will be available 
at the following link: https://fda.zoomgov.com/j/1605634800?pwd=QWlpWUpZUnZTVnZWWUIwckxMRVdZUT09.

[[Page 23523]]

    Passcode: N5v5y*

FOR FURTHER INFORMATION CONTACT: Donna Mendrick, National Center for 
Toxicological Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 32, Rm. 2208, Silver Spring, MD 20993-0002, 301-
796-8892, or FDA Advisory Committee Information Line, 1-800-741-8138 
(301-443-0572 in the Washington, DC area). A notice in the Federal 
Register about last minute modifications that impact a previously 
announced advisory committee meeting cannot always be published quickly 
enough to provide timely notice. Therefore, you should always check the 
Agency's website at https://www.fda.gov/AdvisoryCommittees/default.htm 
and scroll down to the appropriate advisory committee meeting link, or 
call the advisory committee information line to learn about possible 
modifications before coming to the meeting.

SUPPLEMENTARY INFORMATION: 
    Agenda: On May 18, 2022, the Science Advisory Board Chair will 
welcome the participants, and the NCTR Director will provide a Center-
wide update on scientific initiatives and accomplishments during the 
past year. The Science Advisory Board will be presented with an 
overview of the Science Advisory Board Subcommittee Site Visit Report 
and a response to this review. The Center for Biologics Evaluation and 
Research, Center for Drug Evaluation and Research, Center for Devices 
and Radiological Health, Center for Food Safety and Applied Nutrition, 
Center for Tobacco Products, and the Office of Regulatory Affairs will 
each briefly discuss their specific research strategic needs and 
potential areas of collaboration.
    On May 19, 2022, there will be updates from the NCTR Research 
Divisions and a public comment session. Following an open discussion of 
all the information presented, the open session of the meeting will 
close so the Science Advisory Board members can discuss personnel 
issues at NCTR.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its website prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's website after the meeting. Background material is 
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting 
link.
    Procedure: On May 18, 2022, from 8 a.m. to 5:55 p.m., Central 
Standard Time, and May 19, 2022, from 8 a.m. to 11:30 a.m., Central 
Standard Time, the meeting is open to the public. Interested persons 
may present data, information, or views, orally or in writing, on 
issues pending before the committee. Written submissions may be made to 
the contact person on or before May 13, 2022. Oral presentations from 
the public will be scheduled between approximately 1 p.m. and 2 p.m. 
Central Standard Time. Those individuals interested in making formal 
oral presentations should notify the contact person and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time requested to make their presentation 
on or before May 5, 2022. Time allotted for each presentation may be 
limited. If the number of registrants requesting to speak is greater 
than can be reasonably accommodated during the scheduled open public 
hearing session, FDA may conduct a lottery to determine the speakers 
for the scheduled open public hearing session. The contact person will 
notify interested persons regarding their request to speak by May 6, 
2022.
    Closed Committee Deliberations: On May 19, 2022, from 11:30 a.m. to 
12 p.m., Central Standard Time, the meeting will be closed to permit 
discussion where disclosure would constitute a clearly unwarranted 
invasion of personal privacy (5 U.S.C. 552b(c)(6)). This portion of the 
meeting will be closed to permit discussion of information concerning 
individuals associated with the research programs at NCTR.
    Persons attending FDA's advisory committee meetings are advised 
that the Agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
disabilities. If you require accommodations due to a disability, please 
contact Donna Mendrick at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our website at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: April 15, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-08460 Filed 4-19-22; 8:45 am]
BILLING CODE 4164-01-P